Windtree Therapeutics Plunges 77% After BNB Treasury Flop and Nasdaq Delisting
Windtree Therapeutics Crashes 77% After BNB Treasury Failure and Nasdaq Delisting Windtree Therapeutics, a biotech company that pinned its hopes on a BNB treasury strategy, has seen its stock plummet an astonishing 77.2% to just $0.11 after Nasdaq issued a delisting notice for failing to meet the minimum $1 bid price requirement. While BNB, the […]
Read Full Article